SEC Comment Letter for PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Jun 20, 2011
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: June 20, 2011 · CIK: 0001157075 · Accession: 0000000000-11-037604
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-68008
Letter
June 20, 2011 Ms. Patricia Gruden Chief Executive Officer Nuvilex, Inc. 7702 E. Doubletree Ranch Road, Suite 300, Scottsdale, AZ 85258
Re: Nuvilex, Inc. Form 10-K for the Year Ended April 30, 2010 Filed on December 29, 2010 Form 10-Q for Fiscal Quarter Ended July 31, 2010 Filed on January 14, 2011, Amended on April 26, 2011 Form 10-Q for Fiscal Quarter Ended October 31, 2010 Filed on January 28, 2011, Amended on April 26, 2011 File No. 333-68008
Dear Ms. Gruden:
We have completed our review of your f ilings. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi lings to be certain that the filings includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Gus Rodriguez Gus Rodriguez Accounting Branch Chief
Show Raw Text
June 20, 2011 Ms. Patricia Gruden Chief Executive Officer Nuvilex, Inc. 7702 E. Doubletree Ranch Road, Suite 300, Scottsdale, AZ 85258 Re: Nuvilex, Inc. Form 10-K for the Year Ended April 30, 2010 Filed on December 29, 2010 Form 10-Q for Fiscal Quarter Ended July 31, 2010 Filed on January 14, 2011, Amended on April 26, 2011 Form 10-Q for Fiscal Quarter Ended October 31, 2010 Filed on January 28, 2011, Amended on April 26, 2011 File No. 333-68008 Dear Ms. Gruden: We have completed our review of your f ilings. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi lings to be certain that the filings includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Gus Rodriguez Gus Rodriguez Accounting Branch Chief